By Colin Kellaher

 

Shares of Innate Pharma SA tumbled sharply on Monday following the failure of the clinical-stage biotech company's lead partnered asset in a Phase 3 study in head and neck cancer.

The Marseille, France, company said the study evaluating monalizumab in combination with cetuximab versus cetuximab alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck didn't meet a pre-defined threshold for efficacy, and that partner AstraZeneca PLC was pulling the plug on the trial.

Innate, which has licensed full oncology rights to monalizumab to AstraZeneca under a 2015 development and commercialization agreement, said it remains confident in the development program for monalizumab in lung cancer.

Paris-listed shares of Innate were recently down 16% to EUR2.53, while its U.S.-listed shares fell 17% in premarket trading to $2.66.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

August 01, 2022 06:15 ET (10:15 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Août 2022 à Sept 2022 Plus de graphiques de la Bourse Innate Pharma
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Sept 2021 à Sept 2022 Plus de graphiques de la Bourse Innate Pharma